Multinational approach to IP Strategy: Structuring and Managing Global IP in Europe

By Fred Logue Slides presented by Fred Logue at the IPBC China conference.   [This presentation originally appeared on the New Morning Intellectual Property blog.]

When Should a Start-Up Seek Patent Protection?

By Neil Wilkof In carrying out due diligence, how many times have I heard this refrain from a start-up: “Oh yes, we have a couple of a patents or patent applications, but they don’t really address our current activities.” And so I ask–“so what about seeking patent protection for the current activities?” The answer tends […]

Developing a digital copyright strategy

By Heather Ford [This post originally appeared at Heather Ford’s slideshare account.]

Intangible Assets: Nine Facts Management Teams and Boards Absolutely Need To Know!

By Michael D. Moberly 1.  It’s an economic fact that 65+% of most company’s value, sources of revenue, sustainability, and growth potential evolve directly from intangible assets, therefore its all-the-more likely intangible assets will be in play and integral to most deals and/or transactions. 2.  Conventional intellectual property protections issued, i.e., patents, copyrights, trademarks a. […]

Patent Valuation, T.S. Eliot and the Theatre of the Absurd

By Neil Wilkof It is one of the most famous stanzas of modern English language poetry. Thus T.S. Eliot concluded his poem– “The Hollow Men”: This is the way the world ends This is the way the world ends This is the way the world ends Not with a bang but a whimper. And so […]

Rembrandts in the Rear View Mirror: The Demise of Intellectual Capital

By Joseph E. Root For all our otherwise stellar attributes, we patent lawyers are not a very charismatic lot.  The author speaks from within the fraternity, so that statement is a rueful admission, not an accusation.  The fact is, while our college classmates were doing pharmaceuticals, close interpersonal contact and loud, rhythmic music, we spent […]

IP Strategy for Drug Discovery: A Dedicated Research Firm’s Perspective

By Vinita Radhakrishnan Given the nature of business of a dedicated research firm (DRF) in the pharmaceutical sector, intellectual property (IP), particularly, patents are considered to be the most valued asset. More times than not, the standing of a dedicated research firm, in the market place, is judged by the strength and nature of their […]